Applicants,Chemical_Name,Funding_requested_for,Pharmaceutical,Schedules,Therapeutic_group
"BEIGENE NZ UNLIMITED, Janssen, ASTRAZENECA LIMITED",Bruton tyrosine kinase inhibitor (BTKi),"chronic lymphocytic leukaemia, first line monotherapy, with TP53 mutation",Bruton tyrosine kinase inhibitor (BTKi) (Imbruvica),,
